FDA Clinical Hold Lifted with DDReg’s Toxicology Expertise
Customer Requirement A US-based biopharmaceutical company conducting early-phase clinical development encountered a regulatory hurdle when the US FDA placed a clinical hold on its Phase 2 study application for a higher dose. The hold was issued due to toxicological findings observed during preclinical studies. To move forward, the company required scientific rationale and justification to […]
FDA Clinical Hold Lifted with DDReg’s Toxicology Expertise Read More »